Who are Praluent (Alirocumab)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Evolocumab combined with statins, Evolocumab Prefilled Syringe, Repatha®, Evolocumab Pre-filled Syringe.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/praluent-alirocumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Praluent (Alirocumab) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Praluent (Alirocumab) (Praluent (Alirocumab)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PCSK9 inhibitor (monoclonal antibody). Area: Cardiovascular.

marketed PCSK9 inhibitor (monoclonal antibody) PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Praluent (Alirocumab) (Praluent (Alirocumab)) — Federico II University. Alirocumab is a monoclonal antibody that binds to and inhibits PCSK9, a protein that degrades LDL receptors, thereby increasing LDL receptor availability and lowering blood LDL cholesterol.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Praluent (Alirocumab) TARGET	Praluent (Alirocumab)	Federico II University	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
Evolocumab combined with statins	Evolocumab combined with statins	Zibo Central Hospital	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9
Evolocumab Prefilled Syringe	Evolocumab Prefilled Syringe	University of Erlangen-Nürnberg Medical School	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9
Repatha®	Repatha®	Sejong General Hospital	marketed	PCSK9 inhibitor (monoclonal antibody)	PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)
Evolocumab Pre-filled Syringe	Evolocumab Pre-filled Syringe	Amgen	phase 3	PCSK9 inhibitor (monoclonal antibody)	PCSK9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PCSK9 inhibitor (monoclonal antibody) class)

Amgen · 1 drug in this class
Federico II University · 1 drug in this class
Sejong General Hospital · 1 drug in this class
University of Erlangen-Nürnberg Medical School · 1 drug in this class
Zibo Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Praluent (Alirocumab) — Competitive Intelligence Brief. https://druglandscape.com/ci/praluent-alirocumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab